UroOncology Laboratory - LICR Melbourne Centre for Clinical Sciences

MELBOURNE CENTRE FOR CLINICAL SCIENCES

Research > UroOncology Lab

Uro-Oncology Lab

The Uro-Oncology Laboratory is studying cancers related to the urinary system: kidney, prostate and bladder cancers. These cancers are highly prevalent in Australia, but current treatments are not ideal. As we understand the basic biology of these cancers more clearly, we are discovering new potential targets for treatment.

The LICR Uro-Oncology Laboratory, which has very close interactions with the surgeons and cancer specialists who care for these patients, will examine the processes underlying the causes and growth of these cancers.

Research in our laboratory will specifically concentrate on how these cancers use signalling pathways within the cell, how they interact with their environment (particularly with respect to blood vessel growth), how they are recognised by and interact with the immune system, and how these processes correlate with the clinical outcomes and responses to treatment we observe in these patients.

These research projects will involve collaboration with the other research groups within the Melbourne Centre, the LICR's global Angiogenesis Program, and other Australian and international collaborators.

Publications

1.Lawrentschuk N, Bolton D, DAVIS ID and Scott AM. Renal cell cancer and positron emission tomography - an evolving diagnostic and therapeutic relationship. Current Medical Imaging Reviews 3: 17-26, 2007.

2. Lawrentschuk N, DAVIS ID, Bolton DM and Scott AM. Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. International Journal of Urology 14: 89-95, 2007.

3. DAVIS ID, Liu Z, Saunders W, Lee F-T, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss A, Chappell B, Poon A, Saunder T, Hoffman EW, Old LJ and Scott AM. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immunity [serial online] 2007; 7:14. URL: http://www.cancerimmunity.org/v7p14/070714.htm

4. DAVIS ID, Wiseman GA, Lee F-T, Gansen DN, Hopkins W, Papenfuss A, Steinmetz S, Ingle J, Croghan GA, Burch PA, Moynihan TJ, Warnaar S, Ullrich S, Hoffman EW, Old LJ and Scott AM. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immunity [serial online] 2007; 7:13. URL: http://www.cancerimmunity.org/v7p13/070713.htm

5. DAVIS ID, Toner G, Broad A, Campano LM and Rosenthal M. A phase II trial of antiidiotypic p53 peptides (PentrysT) in patients with hormone-refractory prostate cancer. Asia Pacific Journal of Clinical Oncology 3: 1-8, 2007

Click Here For More

Research Links

	Overview
	Tumour Targeting Laboratory
	Cancer Vaccine Laboratory
	T Cell Laboratory
	Uro-Oncology Laboratory
	Mariadason Laboratory
	Joint Austin Ludwig Oncology Unit
	Centre for PET
	Core Groups

Uro-Oncology Lab Staff

Laboratory Head

A/Prof. Ian Davis

Staff Directory

Ian Davis - Laboratory Head
Pavel Sluka - Postdoctoral Fellow
Lekshmy Shanker – Project Co-ordinator
Juliet Quirk - Senior Research Officer
Adee Davidson - M.D. Student
Niero Rajarubendra - M.D. Student

Of Note

Grants

Ian Davis
Victorian Cancer Agency Clinician Researcher Fellowship 2007-2009
Urological Society of Australia 2007-2008
Victorian Cancer Agency Tumour Stream Research Grant 2008-2011
Victorian Cancer Agency Cancer Clinical Trials Grant 2008-2011